PRTG PORTAGE BIOTECH INC

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Portage Biotech to Participate in Panel Discussion During the 2023 BIO International Conference

Ian Walters, M.D. to serve as expert panelist discussing the future of immune checkpoint inhibitors

WESTPORT, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that CEO Dr. Ian Walters will serve as an expert spokesperson on an oncology panel discussion at the upcoming BIO International Conference taking place in Boston, Massachusetts June 5-8, 2023.

Panel Date and Time: Thursday, June 8, 10:15 – 11:15 a.m. ET Session Room 254A

Title: Are We Past the Checkpoint?

Dr. Walters will be joined by industry experts during the panel to explore the future of the immune checkpoint inhibitor (ICI) space and the up-and-coming approaches to reactivating the body's own immune system. The panelists will discuss how the field of immuno-oncology has evolved, strategies to improve success in ICIs and entirely new approaches.

In addition to the panel, members of Portage’s management team will be in attendance to explore potential collaborations and partnerships with other industry leaders.

For more information on the panel and to register, visit the .

About Portage Biotech Inc.

Portage is a clinical-stage immuno-oncology company advancing multi-targeted therapies to extend survival and significantly improve the lives of patients with cancer. Lead programs in the Portage portfolio include first-in-class invariant natural killer T cell (iNKT) small molecule engagers and best-in-class adenosine antagonists. These programs are being advanced using innovative trial designs and translational data to identify the patient populations most likely to benefit from treatment. The Company’s unique business model leverages a strong network of academic experts and large pharma partners to rapidly and efficiently advance multiple products. For more information, please visit , follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations

Chuck Padala

Media Relations

Raena Mina, Ph.D.



EN
01/06/2023

Underlying

PRTGPORTAGE BIOTECH INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PORTAGE BIOTECH INC

 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelio...

Portage Biotech Reports Confirmatory Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 DOVER, Del., April 28, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company today reports confirmatory preclinical efficacy data for PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor. Dr. Luciano Mutti of the Department of Applied Clinical Sciences and Biotechnology at the University of L'Aquila, Italy, an internationally recognized expert in mesothelioma, will be presenting the data at the American Association for C...

April 28, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Reports Promising Preclinical Results in Mesothelioma ...

Portage Biotech Reports Promising Preclinical Results in Mesothelioma Supporting First-In-Human Trial of PORT-7 Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent or in combination with anti-PD-1 antibody DOVER, Del., March 27, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, presented new preclinical data for PORT-7 (TT-4), a selective Adenosine A2B receptor inhibitor, generated by Dr. Luciano Mutti, Gruppo I...

March 27, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation ...

Portage Biotech Resumes Enrollment in Final Cohort of Dose Escalation for Port-6 in ADPORT-601 Trial Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in Patients DOVER, Del., March 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the resumption of patient enrollment in the fourth and final cohort of the dose escalation stage for PORT-6, a highly selective A2A antagonist, wi...

March 12, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Receives Extension of Time to Attain Compliance With S...

Portage Biotech Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements DOVER, Del., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that on February 11, 2025, it received notification from The Nasdaq Stock Market, LLC (“Nasdaq”) that Nasdaq has accepted Portage’s compliance plan and has granted the Company the extension to regain compliance with the continued listing standards on The Nasdaq Ca...

February 12, 2025 1 EN
 PRESS RELEASE
Free
PRTG PORTAGE BIOTECH...

Portage Biotech Announces Completion of $2.15 Million Private Financin...

Portage Biotech Announces Completion of $2.15 Million Private Financing DOVER, Del., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced that it has completed a private placement of $2.15 million from two Portage directors. The 524,390 ordinary shares were sold at $4.10 per share, the Nasdaq official Closing Price on January 22, 2025. Portage intends to use the proceeds from the financing for working capital and other general corporate...

January 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch